News

Novo Nordisk announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has…
Read More...

Johnson & Johnson announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2…
Read More...

Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing…
Read More...

Incyte announced it has entered into an asset purchase agreement with MorphoSys AG which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting…
Read More...

Valneva SE announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million (€95 million). The Company was awarded a…
Read More...

AQEMIA continues to grow rapidly in its effort to discover new drugs with their generative-AI fueled by deep physics. After raising €30M last year, the tech-enabled drug discovery…
Read More...

Regeneron Pharmaceuticals, Inc. announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization…
Read More...

Vertex Pharmaceuticals Incorporated announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain.…
Read More...

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common…
Read More...

GSK plc announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and…
Read More...

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for…
Read More...

Travere Therapeutics, Inc., announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic…
Read More...

Repare Therapeutics Inc. announced that, under its worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, it has earned a $40…
Read More...

Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces an expanded commitment to developing tailored cancer vaccines…
Read More...

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being…
Read More...

Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have…
Read More...

Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc.…
Read More...

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA (erdafitinib) for the treatment…
Read More...